Table 2.
Frequency of aspirin and nonaspirin NSAID use and risk of incident glioma and glioblastoma, NIH-AARP, 1996–2006
| Case | HRa (95%CI) | HRb (95%CI) | |
|---|---|---|---|
| Glioma | |||
| Aspirinc | |||
| No use | 75 | 1.00 (Ref) | 1.00 (Ref) |
| Nonregular | 135 | 1.27 (0.96–1.68) | 1.21 (0.91–1.61) |
| Regular | 127 | 1.31 (0.98–1.74) | 1.16 (0.87–1.56) |
| >2–6 times/wk | 31 | 1.15 (0.77–1.75) | 1.07 (0.70–1.62) |
| 7+ times/wk | 96 | 1.37 (1.01–1.86) | 1.21 (0.88–1.65) |
| P trend | 0.66 | ||
| Nonaspirin NSAIDd | |||
| No use | 149 | 1.00 (Ref) | 1.00 (Ref) |
| Nonregular | 141 | 1.05 (0.83–1.32) | 1.06 (0.84–1.33) |
| Regular | 47 | 0.85 (0.62–1.19) | 0.90 (0.65–1.25) |
| >2–6 times/wk | 17 | 0.83 (0.50–1.38) | 0.87 (0.53–1.44) |
| 7+ times/wk | 30 | 0.87 (0.59–1.28) | 0.92 (0.62–1.36) |
| P trend | 0.59 | ||
| Glioblastoma | |||
| Aspirinc | |||
| No use | 56 | 1.00 (Ref) | 1.00 (Ref) |
| Nonregular | 108 | 1.36 (0.98–1.88) | 1.30 (0.94–1.80) |
| Regular | 96 | 1.32 (0.95–1.84) | 1.17 (0.83–1.64) |
| >2–6 times/wk | 23 | 1.14 (0.70–1.86) | 1.06 (0.65–1.72) |
| 7+ times/wk | 73 | 1.39 (0.98–1.98) | 1.21 (0.84–1.75) |
| P trend | 0.57 | ||
| Nonaspirin NSAIDd | |||
| No use | 118 | 1.00 (Ref) | 1.00 (Ref) |
| Nonregular | 109 | 1.03 (0.79–1.33) | 1.03 (0.79–1.34) |
| Regular | 34 | 0.78 (0.53–1.14) | 0.82 (0.56–1.20) |
| >2–6 times/wk | 9 | 0.56 (0.28–1.10) | 0.58 (0.30–1.15) |
| 7+ times/wk | 25 | 0.91 (0.59–1.41) | 0.96 (0.62–1.49) |
| P trend | 0.87 |
a
Age as time metric.
b
Adjusting for sex, race, and history of heart disease using age as time metric.
c
Four glioblastoma cases were missing for aspirin.
d
Three glioblastoma cases and 1 glioma case were missing for nonaspirin NSAIDs.